BioGend Therapeutics , Ltd. Overview
Get informed when a big investor buys or sells
+ Follow-42.37
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for 6733.TWO is -42.37. That is below the Healthcare sector average of 70.94. Investors often review this figure alongside BioGend Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 6733.TWO currently prints -42.37 for P/E ratio, while the sector average sits near 70.94. That is roughly 159.7% below the sector mean. Large gaps often invite a closer look at BioGend Therapeutics , Ltd.'s growth, margins, and balance sheet.
A P/E ratio of -42.37 for BioGend Therapeutics , Ltd. is not 'good' or 'bad' on its own. Compare it with the peer average (70.94) and with 6733.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting 6733.TWO's P/E ratio (-42.37), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack BioGend Therapeutics , Ltd.'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
